- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/16 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 217/16
Total number of patents in this class: 180
10-year publication summary
10
|
15
|
10
|
14
|
14
|
9
|
8
|
11
|
10
|
4
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Eli Lilly and Company | 3908 |
10 |
Ardelyx, Inc. | 115 |
7 |
Abbvie Inc. | 1802 |
6 |
Tongli Biomedical Co., Ltd | 31 |
6 |
Ctxt Pty Ltd | 53 |
6 |
Astellas Pharma Inc. | 1088 |
5 |
Epizyme, Inc. | 374 |
5 |
Envista | 4 |
4 |
Cytosinlab Therapeutics Co., Ltd. | 15 |
4 |
Novartis AG | 10709 |
3 |
Merck Sharp & Dohme Corp. | 2190 |
3 |
Janssen Pharmaceutica N.V. | 3370 |
3 |
Forma Therapeutics, Inc. | 154 |
3 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3186 |
3 |
Zhejiang University | 3206 |
3 |
Glaxo Group Limited | 4130 |
2 |
F. Hoffmann-La Roche AG | 7947 |
2 |
Abbott Laboratories | 2397 |
2 |
Academia Sinica | 947 |
2 |
Amira Pharmaceuticals, Inc. | 70 |
2 |
Other owners | 99 |